secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2022-02-28T23:59:59+00:00
Accession:  0001628280-22-004080
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia Q4 net revenue $23.4M, FY loss $181M; FY22 LUPKYNIS guidance $115-135M
------------------------------------------------------------------------------

- Q4 2021 net revenue $23.4M (60% increase from Q3); full year net revenue $45.6M.
- Net loss Q4 $33.3M ($0.25/share) vs $8.1M ($0.06) in Q4 2020; full year $181M ($1.40/share).
- FY 2022 LUPKYNIS net revenue guidance $115-135M, representing 150-200% YoY growth.
- Cash, equivalents & investments $466.1M at Dec 31, 2021; raised $196.7M net via ATM at avg $19.91.
- AURORA 2 continuation study shows sustained efficacy; EMA MAA on track for CHMP opinion H2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000162828022004080/0001628280-22-004080-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000162828022004080/auph-20220228.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-004080

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer